In silico quest of selective naphthyl-based CREBBP bromodomain inhibitor

Aparna V, Dineshkumar K, Mohanalakshmi N, Velmurugan D, Hopper W (2014) Identification of natural compound inhibitors for multidrug efflux pumps of Escherichia coli and Pseudomonas aeruginosa using in silico high-throughput virtual screening and in vitro validation. PLoS One 9:e101840 Berman HM et al (2000) The protein data bank. Nucleic Acids Res 28:235–242 Conery AR et al (2016) Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Elife 5:e10483 Das C, Lucia MS, Hansen KC, Tyler JK (2009) CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 459:113–117 Dash R et al (2015) In silico analysis of indole-3-carbinol and its metabolite DIM as EGFR tyrosine kinase inhibitors in platinum resistant ovarian cancer vis a vis ADME/T property analysis. J App Pharm Sci 5(11):073–078 Doman TN et al (2002) Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem 45:2213–2221 Filippakopoulos P, Knapp S (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13:337–356 Florence B, Faller DV (2001) You bet-cha: a novel family of transcriptional regulators. Front Biosci 6:D1008–D1018 Friesner RA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749 Friesner RA et al (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. J Med Chem 49:6177–6196 Giles RH, Peters DJ, Breuning MH (1998) Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14:178–183 Goodman RH, Smolik S (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14:1553–1577 Hammitzsch A et al (2015) CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci 112:10768–10773 Harmange J-C et al (2008) Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. J Med Chem 51:1649–1667 Hay DA et al (2014) Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc 136:9308–9319 Hewings DS et al (2011) 3, 5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem 54:6761–6770 Hou T, Wang J, Li Y, Wang W (2010) Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 51:69–82 Hu X, Hong L, Smith MD, Neusius T, Cheng X, Smith JC (2015) The dynamics of single protein molecules is non-equilibrium and self-similar over thirteen decades in time. Nat Phys 12:171–174 Ito A, Lai CH, Zhao X, Si Saito, Hamilton MH, Appella E, Yao TP (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20:1331–1340 Jacobson RH, Ladurner AG, King DS, Tjian R (2000) Structure and function of a human TAFII250 double bromodomain module. Science 288:1422–1425 Jatana N, Sharma A, Latha N (2013) Pharmacophore modeling and virtual screening studies to design potential COMT inhibitors as new leads. J Mol Gr Model 39:145–164 Jin Q et al (2011) Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J 30:249–262 Kuhn B, Gerber P, Schulz-Gasch T, Stahl M (2005) Validation and use of the MM-PBSA approach for drug discovery. J Med Chem 48:4040–4048 Labute P (2008) The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem 29:1693–1698 Li M et al (2011a) High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med 9:1 Li Y, Yang H-X, Luo R-Z, Zhang Y, Li M, Wang X, Jia W-H (2011b) High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma. Ann Thorac Surg 91:1531–1538 Mujtaba S et al (2004) Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell 13:251–263 Müller S, Knapp S (2014) Discovery of BET bromodomain inhibitors and their role in target validation. MedChemComm 5:288–296 Muller S, Filippakopoulos P, Knapp S (2011) Bromodomains as therapeutic targets. Expert Rev Mol Med 13:e29 Phillips JC et al (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26:1781–1802. https://doi.org/10.1002/jcc.20289 Picaud S et al (2015) Generation of a selective small molecule inhibitor of the CBP/p300 bromodomain for leukemia therapy. Can Res 75:5106–5119 Poplawski A et al (2014) Molecular insights into the recognition of N-terminal histone modifications by the BRPF1 bromodomain. J Mol Biol 426:1661–1676. https://doi.org/10.1016/j.jmb.2013.12.007 Priya Doss CG, Chakraborty C, Chen L, Zhu H (2014) Integrating in silico prediction methods, molecular docking, and molecular dynamics simulation to predict the impact of ALK missense mutations in structural perspective. BioMed Res Int 2014:895831 Rastelli G, Rio AD, Degliesposti G, Sgobba M (2010) Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. J Comput Chem 31:797–810 Romero FA, Taylor AM, Crawford TD, Tsui V, Côté A, Magnuson S (2015) Disrupting acetyl-lysine recognition: progress in the development of bromodomain inhibitors. J Med Chem 59:1271–1298 Rooney TP et al (2014) A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation–π interaction. Angew Chem Int Ed 53:6126–6130 Schrödinger S (2012) Induced fit docking protocol; glide version 5.8, prime version 3.1. Schrödinger LLC, New York Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403:41–45 Talele TT, McLaughlin ML (2008) Molecular docking/dynamics studies of Aurora A kinase inhibitors. J Mol Gr Model 26:1213–1222 Tanwar H, Sneha P, Kumar DT, Siva R, Walter CEJ, Doss CGP (2017) Chapter five-A computational approach to identify the biophysical and structural aspects of methylenetetrahydrofolate reductase (MTHFR) mutations (A222V, E429A, and R594Q) leading to schizophrenia. Adv Protein Chem Struct Biol 108:105–125 Taylor AM et al (2016) Fragment-based discovery of a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor (CPI-637). ACS Med Chem Lett 7(5):531–536 Unzue A, Xu M, Dong J, Wiedmer L, Spiliotopoulos D, Caflisch A, Nevado C (2015) Fragment-based design of selective nanomolar ligands of the CREBBP bromodomain. J Med Chem 59:1350–1356 Unzue A et al (2016) The “Gatekeeper” residue influences the mode of binding of acetyl indoles to bromodomains. J Med Chem 59:3087–3097 Vanommeslaeghe K et al (2010) CHARMM general force field (CGenFF): a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem 31:671–690. https://doi.org/10.1002/jcc.21367 Vidler LR, Brown N, Knapp S, Hoelder S (2012) Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem 55:7346–7359 Weis A, Katebzadeh K, Söderhjelm P, Nilsson I, Ryde U (2006) Ligand affinities predicted with the MM/PBSA method: dependence on the simulation method and the force field. J Med Chem 49:6596–6606 Wichapong K, Rohe A, Platzer C, Slynko I, Erdmann F, Schmidt M, Sippl W (2014) Application of docking and QM/MM-GBSA rescoring to screen for novel Myt1 kinase inhibitors. J Chem Inf Model 54:881–893 Xu M, Unzue A, Dong J, Spiliotopoulos D, Nevado C, Caflisch A (2015) Discovery of CREBBP bromodomain inhibitors by high-throughput docking and hit optimization guided by molecular dynamics. J Med Chem 59:1340–1349